NRX Pharmaceuticals, Inc. Cash and Cash Equivalents
NRX Pharmaceuticals, Inc. (NRXP) had Cash and Cash Equivalents of $26.69 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-14
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $26.69M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $6.71M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $7.80M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $7.18M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $26.69M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $6.71M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $7.80M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $7.18M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $2.91M 10-Q · filed 2025-08-18 |
| 2025-03-31 | $5.55M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.44M 10-K · filed 2026-03-23 |
| 2024-09-30 | $1.65M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.90M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.32M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.59M 10-K · filed 2025-03-14 |
| 2023-09-30 | $8.90M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $14.97M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $16.51M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $20.05M 10-K · filed 2024-03-29 |
| 2022-09-30 | $18.25M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $24.55M 10-Q · filed 2022-08-15 |
| 2021-12-31 | $27.61M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |